# Innovative Hematology

Innovative Hematology is an Endowment / Foundation based in Indianapolis, United States.

## Overview

- **Organization type:** Endowment / Foundation
- **Headquarters:** Indianapolis, United States
- **Region:** North America
- **Address:** 8326 Naab Road, Indianapolis, IN 46260, United States
- **Founded:** 1998
- **Assets under management:** $160M (Altss estimate)
- **Website:** www.innovativehematology.org
- **LinkedIn:** https://www.linkedin.com/company/innovative-hematology-inc

## Regulatory record

- **Reports private funds:** No

## About

Innovative Hematology was established in 1998 by Dr. Amy Shapiro, a hematologist who remains the organization's co-founder, CEO, and Medical Director. The entity functions as the financial and operational backbone of the Indiana Hemophilia and Thrombosis Center (IHTC), a non-profit specialty clinic serving patients with bleeding and clotting disorders. Unlike a traditional medical endowment that merely writes checks to an affiliated hospital, Innovative Hematology is structurally intertwined with the clinic's daily operations, funding comprehensive care delivery, pharmaceutical inventories, and clinical research programs from its own investment base. The foundation deploys capital through a diversified strategy spanning buyouts, growth equity, fund-of-funds commitments, and secondaries. Its investment portfolio is designed to generate returns that sustain the IHTC's dual mission: providing direct patient care and advancing clinical hematology research. The physical asset footprint includes the IHTC headquarters and clinic at 8326 Naab Road in Indianapolis, along with a pharmaceutical inventory managed on-site. The clinic maintains a long-standing clinical training and financial support partnership with the Indiana University School of Medicine, embedding the foundation's capital strategy within a broader academic-medical ecosystem. The board combines deep clinical and entrepreneurial experience. Chairman Phillip Himelstein is also a founder of The Sage Group, a Los Angeles-based merchant bank. Board member Jeff Martin operates Hills Ventures, adding early-stage investment perspective to the investment committee. Eddie Williams, a senior executive at BiomX and Ascendis Pharma, contributes public-market biopharmaceutical expertise. The foundation is a founding member of the American Thrombosis and Hemostasis Network and holds a Center of Excellence designation from Cure HHT for treating hereditary hemorrhagic telangiectasia, a rare vascular disorder. What distinguishes Innovative Hematology structurally is the absence of a financial-services intermediary. The foundation directly owns and operates a federally recognized hemophilia treatment center, making its investment returns directly visible in patient outcomes rather than annual grant reports. There is no university endowment office or hospital finance department mediating between the investment portfolio and the clinical mission. This model — a self-contained clinical-investment entity — is rare among disease-specific foundations, most of which outsource both care delivery and investment management to separate institutions.

## Sectors

- Healthcare Services

## People

- Dr. Amy Shapiro — Co-founder, CEO, and Medical Director
- Phillip Himelstein — Chairman of the Board
- Jeff Martin — Board Member
- Eddie Williams — Board Member

## Questions

### Who runs investment decisions at Innovative Hematology?

Investment oversight is managed through the board of directors, which includes Chairman Phillip Himelstein, a founder of merchant bank The Sage Group, and board member Jeff Martin of Hills Ventures. The organization has not publicly disclosed a dedicated chief investment officer. The board's combined experience in merchant banking, early-stage venture, and biopharmaceutical operating roles shapes the investment strategy.

### Does Innovative Hematology invest directly or only through funds?

The foundation's investment strategy includes direct investments through buyouts and growth equity, alongside fund-of-funds commitments and secondary-market purchases. This hybrid posture allows the endowment to blend its own deal exposure with diversified manager access, though specific direct holdings have not been publicly itemized.

## Related profiles

- [Gloucester Contributory Retirement System](https://altss.com/profile/gloucester-contributory-retirement-system)
- [Pachulski Stang Ziehl & Jones](https://altss.com/profile/pachulski-stang-ziehl-jones)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/innovative-hematology-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology